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Cervical cancer is the third most common cancer in women world-
wide, and it is the leading cause of cancer death among women in 
some areas (1). Approximately 85% of cervical cancers occur in 
developing  countries  without  effective  screening  programs  (1). 
Administering prophylactic human papillomavirus (HPV) vaccines 
to susceptible populations of young women could reduce a large 
fraction of the disease burden.
The standard three-dose regimen of either Cervarix, the biva-
lent  HPV16/18  vaccine  with  AS04  adjuvant  (GlaxoSmithKline 
Biologicals,  Rixensart,  Belgium),  or  Gardasil,  the  quadrivalent 
HPV6/11/16/18 vaccine (Merck and Co, Whitehouse Station, NJ) 
prevents  HPV16  and  HPV18  infections  and  related  cervical 
precancers among unexposed women (2,3). Currently, the cost of 
these regimens and logistical difficulties associated with adminis-
tering three doses over 6 months make it impractical to vaccinate 
preadolescent and young adult women in developing countries (4). 
Even in developed countries, vaccine programs often do not suc-
cessfully administer all three doses; in the United States, a mi-
nority  of  vaccinees  complete  the  full  vaccine  course  (5);  in 
countries that have school-based health programs, such as Australia 
(6) and the United Kingdom (7), vaccine uptake is higher. If vacci-
nation with fewer than three doses were to retain the high efficacy 
of the standard regimen, the ability to vaccinate more women for 
the same cost could translate to a greater public health benefit in 
underserved areas.
Women  in  our  clinical  trial  in  Costa  Rica  were  randomly 
assigned  to  receive  three  doses  of  either  Cervarix  or  control 
vaccine, yet approximately 20% received fewer than three doses 
mostly because of pregnancy and referral to colposcopy. Here, we 
compare the efficacy of fewer than three doses of this HPV vaccine 
vs the standard regimen to prevent newly detected persistent 
HPV16 and HPV18 infections.
Methods
The 7153 women included in the present evaluation are among the 
participants  in  an  ongoing  randomized  clinical  trial  of  7466 
women (8,9). The primary aim of the trial is to evaluate the 
efficacy of a three-dose regimen of the Cervarix vaccine to prevent 
persistent type-specific infection with HPV16 or HPV18 and the 
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subsequent development of HPV-associated precancerous lesions 
(8,10).
In June 2004 and December 2005, the study enrolled young 
women who resided in the regions of Guanacaste and Puntarenas, 
Costa Rica, and were identified via a census. To be eligible, women 
were required to be 18–25 years of age, in good general health, 
and neither pregnant nor breastfeeding. Women were excluded 
if they had a preexisting medical condition that would preclude 
vaccination, a history of hepatitis A infection or previous vaccina-
tion against hepatitis A, or if they were unwilling to use contra-
ception during the vaccination period. The trial was approved by 
human subjects review committees of the US National Cancer 
Institute and Instituto Costarricense de Investigación y Enseñanza 
en Nutrición y Salud (INCIENSA) in Costa Rica. In the United 
States, it was registered as Clinical Trial number NCT00128661.
At the enrollment visit and following informed consent, a risk 
factor  interview  was  administered,  a  pelvic  examination  was 
performed on sexually experienced women, exfoliated cells were 
collected in PreservCyt liquid medium (Cytyc Corp, now Hologic, 
Marlborough, MA) for Thinprep (Cytyc Corp) cytological evalua-
tion and HPV DNA testing, and blood was collected (for 90% of 
women, 30 mL; for the 10% of women in our immunogenicity 
subcohort,  70  mL).  Then,  women  were  randomly  assigned   
in  a  double-blinded  fashion  to  receive  either  Cervarix  or  a   
“control” hepatitis A vaccine (a modified preparation of Havrix; 
GlaxoSmithKline Biologicals) (0.5 mL per dose). Both vaccines 
had identical packaging and were intended to be administered at 0, 1, 
and 6 months. At the 6-month vaccination visit, sexually experi-
enced women self-collected a cervicovaginal exfoliated cell spec-
imen for HPV DNA testing. Women who were not vaccinated in 
the allowable time frames (ie, 21–120 days and 121–300 days after 
enrollment for doses two and three, respectively) did not receive 
the dose. Women who became pregnant during the vaccination 
phase or who were referred to colposcopy were deferred, so that 
they missed the dose if the vaccination window was missed. A Data 
Safety Monitoring Board reviewed safety data annually during the 
vaccination phase and as needed during the follow-up period (final 
review: November 10, 2010).
The protocol required all women to be seen each year during 
the 4 years of follow-up. At each annual study visit, clinicians col-
lected exfoliated cells from sexually active women for cytological 
evaluation and HPV DNA testing. Women found to have low-
grade squamous intraepithelial neoplasia (LSIL) or HPV-positive 
atypical squamous cells of undetermined significance (ASCUS) 
underwent the same procedures at 6-month intervals for safety 
until three consecutive normal cytological results, when they 
returned to yearly follow-up. Women with evidence of high-
grade  disease  or  persistent  low-grade  abnormalities  were 
referred to colposcopy for evaluation and treatment if needed. 
After  the  4-year  visit,  a  modified  algorithm  for  colposcopic   
referral,  biopsy,  and  treatment  was  applied  to  assure  safety   
of  participants  at  the  completion  of  the  initial  4-year  study   
period (8).
Cervical samples were shipped from the clinic to the laboratory 
in Costa Rica in controlled temperature coolers. Duplicate 0.5 mL 
aliquots were made for HPV DNA testing by polymerase chain 
reaction (PCR), and they were frozen in liquid nitrogen. These 
samples were stored frozen in the repository in Costa Rica and 
then shipped in frozen batches to the Netherlands for HPV DNA 
analysis.
PCR-based HPV DNA testing was performed using the SPF10 
PCR primer system and a DNA enzyme immunoassay detection of 
amplimers (DEIA; DDL Diagnostic Laboratory, Voorburg, the 
Netherlands) (11). Briefly, 10 µL proteinase K–treated DNA was 
added to 40 µL of PCR mix. The SPF10 PCR primer set amplifies 
a small fragment of 65 bp from the L1 region of mucosal HPV 
genotypes. Amplification products were detected using the HPV 
SPF10 PCR DEIA system. DEIA-positive SPF10 amplimers were 
used to identify the HPV genotype by reverse hybridization with 
the HPV line probe assay (LiPA25), containing probes for 25 
different HPV genotypes (HPV genotypes 6, 11, 16, 18, 31, 33, 
34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 
70,  and  74;  SPF10  HPV  LiPA25  version  1  [Labo  Biomedical 
Products, Rijswijk, the Netherlands, based on licensed Innogenetics 
technology]) (12). To ensure that HPV16 and HPV18 infections 
were not missed, all specimens that were positive for the presence 
of HPV DNA using the SPF10 DEIA assay but negative for pres-
ence of HPV16 or HPV18 by the LiPA25 assay were also tested 
with type-specific PCR primer sets used to selectively amplify a 
92  bp  HPV16  E7  fragment  (TS16)  and  a  126  bp  HPV18  L1 
fragment (TS18). Amplimers from the type-specific PCRs were 
detected by DEIA, similar to the method for SPF10 amplimer 
detection (13).
CONTEXT AND CAVEATS
Prior knowledge
The HPV16/18 vaccine Cervarix is normally given in three doses. 
Previously, there were no efficacy data to establish whether fewer 
doses might protect women against cervical cancer.
Study design
Data were taken from the Costa Rica vaccine trial, in which many 
of the 7153 women missed one or more of three prescribed doses 
of a randomly assigned HPV16/18 vaccine or control (hepatitis A) 
vaccine mostly because of pregnancy and referral to colposcopy. 
Vaccine efficacy was evaluated in each dosage group by determi-
nation,  via  HPV  DNA  testing,  of  the  number  of  newly  detected 
HPV16 or HPV18 infections that persisted at least 1 year.
Contribution
The estimated vaccine efficacy against infection with HPV16 and 
HPV18 was similar whether the woman received one, two, or all 
three doses.
Implication
It appears that two doses, or even one dose, of the HPV16/18 vac-
cine, is highly efficacious in protecting against persistent HPV16/18 
infections.
Limitations
It is still not known whether the three-dose regimen might provide 
longer duration of protection or more cross-protection against 
heterologous HPV types and whether the findings in this trial are 
applicable to populations in other geographical settings or to other 
HPV vaccines.
From the Editors
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Statistical Analysis
Results follow a statistical analysis plan that was prepared before the 
investigation of this question was initiated. Fieldwork is ongoing, 
and individual information remains blinded. Analyses were therefore 
conducted by an external group, Information Management Systems 
(Rockville,  MD),  under  the  direction  of  the  investigators  who 
remained masked to individual random assignments.
All women were included in the analysis except those who were 
both HPV16 and HPV18 DNA positive at enrollment or had no 
follow-up visits post-enrollment. Women in the HPV and control 
arms were grouped according to the number of doses they received. 
Reasons for not receiving the full-dosing regimen were compared 
by use of the x2 test for categorical variables. Median follow-up 
time from enrollment was calculated in months by arm and dose 
and compared by use of the nonparametric Kruskal–Wallis test.
The primary endpoint for this analysis was a newly detected 
HPV16 or HPV18 infection that persisted for at least 10 months, 
which is an intermediate cancer endpoint that is associated with 
development of cervical intraepithelial neoplasia 3 (14). The def-
inition of that endpoint (persistent infection) required two de-
tections of infection by the same HPV type that occurred at least 
10 months apart with no intervening negative tests. We required 
the first detection of the infection to be at the 6-month vaccine 
visit or later to avoid misclassification of infections prevalent at 
enrollment.  In  this  woman-level  analysis,  each  woman  could 
only contribute once to the numerator (number of women who 
had an incident persistent HPV16 and/or HPV18 infection) and 
denominator (all women with at least one study visit post-enroll-
ment and HPV 16 and/or HPV18 DNA negative at enrollment), 
even if multiple HPV types were detected. Furthermore, HPV in-
fection status was assessed at both regular and colposcopy study 
visits.
We  evaluated  6-month  persistence  as  a  secondary  endpoint 
because it is more distal to precancer; 6-month persistence was 
defined as two or more positive tests for a given HPV type that 
occurred at least 4 months apart with no intervening negative tests. 
We also assessed VE for incident 12-month persistent HPV31, 
HPV33, and HPV45 infections combined because these are the 
HPV types for which there is prior evidence of vaccine cross-
protection (2,10); in this analysis, we excluded women with prevalent 
HPV31, HPV33, and HPV45 infections detected at enrollment. 
The endpoint for this analysis was defined as a new type-specific 
HPV31, HPV33, or HPV45 infection that was first detected at the 
6-month vaccine visit or later, and again at a visit at least 10 months 
later,  with  no  intervening  negative  tests  for  the  HPV  type  in 
question.
For each dose group and arm, we defined the attack rate as the 
proportion of the number of events among the number of women 
over the 4 years of the study. Any difference in the attack rates 
among women who received one, two, or three doses of the 
control  vaccine  could  reflect  random  variation  or  underlying   
differences in the risk of incident infection by the number of doses; 
the absence of a difference in the attack rates in the control vaccine 
arm (in which women are not protected from HPV infections 
unlike the HPV vaccine arm) would indicate that determinants of 
risk, like sexual behavior, are not biasing the comparison between 
number of doses received.
Within each dosage group, the complement of the ratios of the 
attack rates for the HPV and the control arms are the VE estimates. 
We used data from the control arm, instead of directly comparing 
by the number of doses within the HPV arm alone, because we were 
not certain whether the risk of a new persistent HPV16 or HPV18 
infection might vary by number of doses received, even if no HPV 
vaccine  had  been  administered.  We  calculated  exact  confidence 
intervals (15) for VE based on the binomial distribution of the 
number of events in the HPV arm among the total number of events 
in the HPV and control arms. The exact confidence limits for VE 
use numerators of the attack rates based on the product of the total 
number of events and the exact binomial limit (16).
The VE estimate for three doses is presented in this article 
to compare that for two doses and one dose. The three-dose VE 
estimate in the current analysis, however, differs from our previ-
ously presented estimate (90.9% for according to protocol efficacy) 
(10) because of slightly different analytical cohorts: the present 
analysis did not exclude based on disease, treatment, or vaccination 
windows, and it counted outcomes starting at the 6-month visit 
instead of the 12-month visit.
If we found statistically significant evidence (ie, a 95% CI ex-
cluding zero) that two or one dose(s) of vaccine conferred VE, we 
calculated the ratios of VEs for two vs three doses and for one vs three 
doses and their corresponding 95% confidence intervals using an 
unconditional bootstrap percentile method (17) with 1000 bootstrap 
datasets, where resampling was done with replacement. Because the 
cost of administering a series of vaccinations is approximately propor-
tional to the number of doses given, we prespecified that a ratio of 2:3 
for the VEs of HPV in women who received two and three doses 
would reflect equal efficacy per dose and per cost. Thus, we would 
claim that vaccination with fewer than three doses was successful if we 
rejected  a  one-sided  test  of  the  null  hypothesis  that  the  ratio  of   
the two-dose and three-dose VEs equals two-thirds, equivalent to the 
lower bound of the 95% confidence interval for the estimate of the 
ratio being above two-thirds. For one dose, the corresponding crite-
rion for claiming a positive result is that the lower bound of the 95% 
confidence interval for the estimate of the ratio is above one-third.
The 12 months of persistence required for the endpoint began 
with  an  incident  infection  at  the  6-month  visit,  when  the  final 
vaccine dose was scheduled to be administered, or later. A sensi-
tivity  analysis  that  included  only  infections  incident  at  the 
12-month visit or later as endpoints addressed the possibility of 
bias  from  differential  assessment  of  outcomes  in  women  who 
missed vs received the 6-month vaccination.
The present analysis contains updated data until June 21, 2010, 
when the analytical database was frozen; using the available data at 
the initial January 1, 2010 data lock point, statistically significant 
vaccine efficacy (VE) was observed by dose (VE for three doses = 
78%, 95% confidence interval [CI] = 67% to 86%; VE for two 
doses = 82%, 95% CI = 43% to 96%; VE for one dose = 100%, 
95% CI = 57% to 100%).
Results
Of the 24 467 women who we screened, 7466 women were enrolled 
and were randomly assigned to the HPV16/18 vaccine Cervarix or 
to a control vaccine for hepatitis A (Figure 1). We excluded women jnci.oxfordjournals.org    JNCI | Articles 1447
who  had  no  post-enrollment  visits  or  who  were  HPV16  and 
HPV18 DNA positive at enrollment (155 in the HPV vaccine arm; 
158 in the control vaccine arm); the analytic cohort comprised 
5967 women who received three doses (of whom 2957 received the 
HPV vaccine and 3010 received the control vaccine), 802 women 
who received two doses (of whom 422 received the HPV and 380 
received the control vaccine), and 384 women who received one 
dose (of whom, 196 received the HPV and 188 received the con-
trol vaccine) (P for differences in the number of women receiving 
the HPV vaccine vs the control vaccine by dose = 0.23). Median 
time of follow-up from date of first vaccine administration was 
50 months (4.2 years) and was similar between arms within dose.
Participants’ reasons for not receiving all doses were similar in 
both arms conditional on the number of doses actually received 
(P > .05 for all comparisons; Table 1). The most common reasons 
for not receiving all three doses were involuntary, including preg-
nancy and colposcopy referral; it was less common for participants 
to refuse the vaccine.
For all dosage groups, women who received the HPV vaccine 
vs the control vaccine were comparable with respect to age at entry 
and total number of visits (Table 2). Among those who received 
two doses or one dose of the vaccine, HPV16 and HPV18 DNA 
and serologic status at enrollment were comparable by arm within 
each dose group. Among women who received three doses, we 
observed no differences in serologic status at enrollment; however, 
women in the control group were marginally more likely to have 
been HPV16 and/or HPV18 DNA positive at enrollment than 
women who received the HPV vaccine (8.9% vs 7.5%, P = .05), as 
noted previously (8,9). In the control arm, the attack rates of inci-
dent HPV16 or HPV18 infections that persisted for 1 year were 
Table 1. Reasons for missing doses among women who received two doses or one dose of vaccine*
Reason for missed dose
Missing second or third dose, 
among women who received  
two doses
Missing second dose,  
among women who received  
one dose†
Missing third dose, among  
women who received  
one dose†
HPV, No. (%) Control, No. (%) HPV, No. (%) Control, No. (%) HPV, No. (%) Control, No. (%)
Pregnancy 155 (31.8) 145 (32.9) 35 (12.6) 35 (12.8) 50 (18.1) 57 (20.8)
Colposcopy referral 13 (2.7) 12 (2.7) 57 (20.6) 45 (16.4) 57 (20.6) 42 (15.3)
Medical condition 79 (16.2) 66 (15.0) 49 (17.7) 60 (21.9) 43 (15.5) 57 (20.8)
Vaccine refusal by participant 63 (12.9) 58 (13.2) 42 (15.2) 38 (13.9) 87 (31.4) 84 (30.7)
Missed study visit 98 (20.1) 96 (21.8) 58 (20.9) 55 (20.1) 20 (7.2) 23 (8.4)
Other‡ 80 (16.4) 64 (14.5) 36 (13.0) 41 (15.0) 20 (7.2) 11 (4.0)
*  This table includes all vaccinated women to prevent unblinding that could happen with cells that had small sample size (ie, fewer than five women). HPV = 
human papillomavirus.
†  For women who received only one dose, it was possible to have different reasons for missing each of the two subsequent doses.
‡  The three most common “other” reasons included: the woman could not get time off from work to come into the clinic for a vaccination, personal reasons, or 
the woman was not using an acceptable form of birth control.
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Figure 1. CONSORT diagram of women in 
the  Costa  Rica  Vaccine  Trial.  The  primary 
aim of the trial was to evaluate the efficacy 
of  a  three-dose  regimen  of  the  Cervarix 
vaccine  to  prevent  persistent  type-specific 
infection with HPV16 or HPV18 and the 
subsequent development of HPV-associated 
precancerous  lesions.  Although  7466 
women were randomized to receive three 
doses of either Cervarix or control vaccine, 
approximately  20%  received  fewer  than 
three doses of Cervarix or control vaccine 
mostly because of pregnancy and referral to 
colposcopy. Thus, we were able to investi-
gate the protection afforded by two and one 
dose(s) of the HPV vaccine because the cost 
and  logistical  difficulties  of  the  standard 
three-dose  vaccine  regimen  compromises 
implementation.  Asterisk  indicates  that 
four  women  received  discordant  vaccines 
(one  woman  was  enrolled  twice  and 
received three doses of each vaccine and 
three  women  received  two  doses  of  one 
vaccine and one dose of the other vaccine). 
For the purpose of this analysis, the control 
dosing was ignored and they were catego-
rized based on the number of HPV vaccines 
they received. Dagger indicates that women 
who were both HPV16 and HPV18 DNA 
positive  at  enrollment  were  excluded,   
as were women with no follow-up visits 
post-enrollment.1448   Articles | JNCI  Vol. 103, Issue 19  |  October 5, 2011
similar among women who received three doses (4.4%), two doses 
(4.5%), or one dose (5.3%) indicating that they were at similar risk 
for acquiring HPV infections regardless of the number of doses 
received (Table 3).
VE for three doses against newly detected HPV16 or HPV18 
that  persisted  at  least  1  year  was  80.9%  (95%  CI  =  71.1%  to 
87.7%; 25 and 133 events in the HPV and control arms, respec-
tively), for two doses was 84.1% (95% CI = 50.2% to 96.3%; three 
and 17), and for one dose was 100% (95% CI = 66.5% to 100%; 
zero and 10); no statistically significant trend for increasing VE 
with fewer doses was observed (Ptrend = .21) (Table 3). VE results 
were similar for the 6-month persistent HPV16 and/or HPV18 
Table 2. Participant characteristics by number of vaccine doses received and vaccine arm*
Characteristic
One dose† Two doses† Three doses†
HPV, No. (%) Control, No. (%) HPV, No. (%) Control, No. (%) HPV, No. (%) Control, No. (%)
Age at entry, y‡
  18–19 53 (27.0) 52 (27.7) 140 (33.2) 143 (37.6) 933 (31.6) 982 (32.6)
  20–21 56 (28.6) 49 (26.1) 117 (27.7) 85 (22.4) 739 (25.0) 725 (24.1)
  22–23 42 (21.4) 40 (21.3) 90 (21.3) 80 (21.1) 661 (22.4) 704 (23.4)
  24–25 45 (23.0) 47 (25.0) 75 (17.8) 72 (18.9) 624 (21.1) 599 (19.9)
No. of clinic visits attended§
  1–2 13 (6.6) 17 (9.0) 36 (8.5) 37 (9.7) 74 (2.5) 68 (2.3)
  3–5 96 (49.0) 99 (52.7) 275 (65.2) 224 (58.9) 1912 (64.7) 1867 (62.0)
  6–8 67 (34.2) 62 (33.0) 97 (23.0) 106 (27.9) 813 (27.5) 896 (29.8)
  ≥9 20 (10.2) 10 (5.3) 14 (3.3) 13 (3.4) 158 (5.3) 179 (5.9)
Median (IQR) 5 (4 to 7) 5 (4 to 7) 5 (4 to 6) 5 (4 to 6) 5 (5 to 6) 5 (5 to 6)
HPV16/18 DNA status at enrollment||
  Negative¶ 245 (88.4) 241 (88.0) 438 (89.8) 403 (91.4) 2742 (92.5) 2751 (91.1)
  Positive# 32 (11.6) 33 (12.0) 50 (10.2) 38 (8.6) 223 (7.5)** 270 (8.9)
HPV16/18 serostatus at enrollment||
  Negative 173 (62.5) 165 (60.2) 294 (60.2) 269 (61.0) 1899 (64.0) 1899 (62.9)
  Positive# 104 (37.5) 109 (39.8) 194 (39.8) 172 (39.0) 1066 (36.0) 1122 (37.1)
*  IQR = interquartile range; HPV = human papillomavirus.
†  The women who received discordant vaccines were categorized according to the number of HPV vaccine doses they received.
‡  Two women enrolled at age 17 years were included in the 18–19 year age group; one woman enrolled at age 26 and one woman enrolled at age 27 were in-
cluded in the 24–25 year age group.
§  Includes clinic visits for vaccination, annual screening, colposcopy, and treatment (when needed).
||  Data on HPV16 and HPV18 status at enrollment include all vaccinated women to prevent unblinding that could happen with cells that had small sample 
size (ie, fewer than five women).
¶  Included in the negative category are virgins (who did not provide a cervical specimen for HPV testing) and three women who were missing enrollment HPV 
polymerase chain reaction results
#  Indicates positive for either or both HPV16 and HPV18 at enrollment.
** Women in the control group who received three doses were marginally more likely to be HPV16 and/or HPV18 DNA positive at enrollment compared with 
women who received three doses of the HPV vaccine (8.9% vs 7.5%, P = .05 using two-sided test of equality of proportions), as noted previously (8,9).
Table 3. Estimated vaccine efficacy against 12-month incident persistent infection for women who received one, two, and three doses 
of a HPV vaccine compared with a control vaccine
Doses, No. Arm
Women,  
No.
Events,  
No.
Proportion of women with incident,  
12-month persistent HPV16 or  
HPV18 infections, % (95% CI)*
HPV vaccine  
efficacy, %  
(95% CI)*
Efficacy relative to 
three-dose regimen,  
% (95% CI)*
3 (standard  
  regimen)†
Control 3010 133 4.4% (3.7% to 5.2%) 80.9% (71.1% to 87.7%) Referent
HPV 2957 25 0.85% (0.56% to 1.2%)
2‡ Control 380 17 4.5% (2.7% to 6.9%) 84.1% (50.2% to 96.3%) 104% (69.3% to 129%)
HPV 422 3 0.71% (0.18% to 1.9%)
1 Control 188 10 5.3% (2.7% to 9.3%) 100% (66.5% to 100%) 124%§
HPV 196 0 0.0% (0.0% to 1.5%)
*  Human papillomavirus = HPV; 95% CI = 95% confidence interval.
†  The distribution of the time at diagnosis of the case patients in the HPV and control arms was qualitatively assessed to determine whether the protection 
afforded by two doses may be short lived compared with that of three doses. Twenty (80.0%) of 25 breakthrough 1-year persistent HPV infections in the vaccine 
arm were first detected in the first year of follow-up (suggesting missed prevalent infections at enrollment) compared with 40 (30.1%) of 133 infections detected 
in the control arm. Sixteen (64.0%) of 25 breakthrough infections occurred among women who were HPV16 seropositive at enrollment.
‡  One of the three breakthrough infections was detected in each of the first 3 years of the study compared with 0%, 64.7%, 23.5%, and 11.8% of the 17 infec-
tions in years 1, 2, 3, and 4 of the study, respectively. One (33.3%) of the three breakthrough infections occurred in a woman who was HPV16 seropositive at 
enrollment.
§  No bootstrap confidence interval could be estimated due to the presence of zero events in the HPV arm after one dose of vaccine.jnci.oxfordjournals.org    JNCI | Articles 1449
infection endpoint (Supplementary Table 1, available online). 
Although we did see cross-protection against incident 1-year per-
sistent infection with HPV31, HPV33, and HPV45 combined in 
women  who  received  the  standard  three-dose  regimen  (41.3% 
[95% CI = 18.9% to 57.9%]; 57 and 99 events in the HPV and 
control arms, respectively) (8), there was no evidence of such cross-
protection in women who received two doses: 225.9% (95% 
CI = 2334% to 61.1%; seven and five). The small number of total 
events (n = 7) limited our ability to evaluate cross-protection 
among women who received only one dose.
Because there was statistically significant evidence that two doses 
or even one dose of the vaccine had VE against HPV16 and HPV18 
(ie, for all VEs, the lower bound of the 95% CI was substantially 
greater than 0%), we computed the ratios of the VEs for fewer 
than three doses vs full regimen. The ratio of 2:3 dose VEs was 
104% (95% CI = 69.3% to 129%), consistent with two doses 
being more than two-thirds as effective as three doses (Table 3). 
The 1:3 ratio of VEs was 124%, but no bootstrap confidence 
interval could be estimated because of the absence of events in 
the HPV arm.
In the sensitivity analysis that investigated the potential bias 
from differential assessment of outcomes by dose, VEs excluding 
the 6-month study visit were comparable: 82.4% (95% CI = 72.7% 
to 89.0%) for three doses, 84.1% (95% CI = 50.2% to 96.3%) for 
two doses, and 100% (95% CI = 66.5% to 100%) for one dose.
Discussion
We investigated the protection afforded by two and one dose(s) of 
the HPV vaccine because the cost and logistical difficulties of the 
standard  three-dose  vaccine  regimen  compromises  implementa-
tion of this life-saving measure in resource-poor settings. Nested 
within our phase III randomized clinical trial in Costa Rica, we 
provide the first clinical evidence that two doses of the bivalent 
HPV vaccine are highly efficacious in the prevention of incident 
HPV16 and HPV18 infections that persist for at least 1 year 
(VE = 84.1% [95% CI = 50.2% to 96.3%]), and that even a single 
dose may be highly efficacious (VE = 100% [95% CI = 66.5% 
to 100%]).
Although this analysis was not randomized, the attack rates of 
new infections were essentially equal among women who received 
one, two, and three doses of the control vaccine. Equal attack rates 
in the control arm suggested that risks of infection were the same 
regardless of number of doses received. Furthermore, pregnancy, 
the most common reason that women received a reduced number 
of doses, was unrelated to vaccine assignment (18) and therefore 
unlikely to bias the VE estimates. These observations provide sup-
port for the robustness of our analysis.
Further evaluation of the efficacy of one dose is particularly 
important for several reasons. The protection afforded by a single 
dose of vaccine was unexpected because other subunit vaccines 
typically require boosting following the prime dose to confer long-
term protection, although perhaps many of our sexually active 
participants had been previously exposed to HPV16 or HPV18. 
Also, the number of events (N = 10 for ≥12-month persistent 
infection; N = 15 for ≥6-month persistent infection) was small, and 
follow-up time was limited.
Available evidence from immunologic studies supports our effi-
cacy findings. Girls who received two and three doses of Gardasil 
had similar antibody titers several years post-vaccination (19). 
Women in the control arm of our trial with relatively high anti-
body titers after natural infection were partially protected against 
subsequent incident HPV16 and HPV18 infection (20). However, 
the exact relationship between these antibody markers and future 
risk of disease is not clear.
Important questions remain unanswered. The full three-dose reg-
imen may confer greater cross-protection (2,10) against heterologous 
HPV types, as suggested by the limited evidence here. Additionally, 
data from a trial of the bivalent HPV16/18 vaccine in Costa Rica may 
not apply to other vaccine formulations (such as the quadrivalent 
HPV vaccine with alum adjuvant) or to other populations who may 
have more comorbidities than our study population (eg, endemic 
parasitic infections that could, in turn, produce malnutrition and 
possibly a less robust immune response). Finally, the duration of 
protection for fewer than three doses must be quantified. Future 
studies,  such  as  the  cluster-randomized  trial  that  is  being  con-
ducted in India by the World Health Organization, are the next 
critical step in addressing these important research questions.
Our clinical efficacy data provide suggestive evidence that an 
HPV vaccine program that could vaccinate 50% more women with 
a two-dose regimen could potentially reduce cervical cancer inci-
dence more than a standard three-dose program that uses the same 
number of total doses but in fewer women. Surveillance of the 
ongoing programs with extended intervals (vaccination at 0, 6, and 
60 months), such as those currently implemented in Quebec and 
Mexico, can monitor the short-term effectiveness of administering 
fewer than three doses. If randomized studies and cost-effectiveness 
analyses confirm the net benefits of administering fewer doses, and 
the duration of protection is sufficient, then the need for fewer 
doses may make primary prevention of cervical cancer a reality, 
especially for women in areas where most cervical cancers occur.
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